Stock Taper
Zura Bio Limited is a San Diego-based clinical-stage biotech developing novel immune and inflammatory therapies, including ZB-168 and Torudokimab, currently in Phase 2 trials.

Tiburizumab, Zura Bio's lead investigational tetravalent bispecific antibody, targets IL-17A and BAFF to treat autoimmune diseases, currently in Phase 2 trials for systemic sclerosis and hidradenitis suppurativa.
Overall rating: C-
| PEER | PRICE | |
|---|---|---|
ASMB | $34.07 | COMPARE |
ARCT | $15.19 | COMPARE |
ENTA | $13.60 | COMPARE |
FHTX | $6.00 | COMPARE |
SGMT | $10.55 | COMPARE |
PYXS | $3.23 | COMPARE |
IMRX | $4.99 | COMPARE |
TNYA | $0.69 | COMPARE |